TY - STD TI - Cain WJ, Millar JS, Himebauch AS, Tietge UJF, Maugeais C, Usher D, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. Journal of lipid research [internet]. 2005;46:2681–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16150825. UR - http://www.ncbi.nlm.nih.gov/pubmed/16150825 ID - ref1 ER - TY - STD TI - O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation [internet]. 2019;139:1483–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30586750. UR - http://www.ncbi.nlm.nih.gov/pubmed/30586750 ID - ref2 ER - TY - STD TI - Van Capelleveen JC, van der Valk FM, Stroes ESG. Current therapies for lowering lipoprotein (a). Journal of lipid research [internet]. 2016;57:1612–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637277, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5003159. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5003159 ID - ref3 ER - TY - STD TI - Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. Journal of the American College of Cardiology [internet]. 2014;63:1278–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24509273. UR - http://www.ncbi.nlm.nih.gov/pubmed/24509273 ID - ref4 ER - TY - STD TI - Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. Journal of lipid research [internet]. 2016;57:1086–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27102113, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4878192. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4878192 ID - ref5 ER - TY - STD TI - Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. The journal of biological chemistry [internet]. 2015;290:11649–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25778403, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4416867. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4416867 ID - ref6 ER - TY - STD TI - Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. European heart journal [internet]. 2019;1:1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31111151. UR - http://www.ncbi.nlm.nih.gov/pubmed/31111151 ID - ref7 ER - TY - STD TI - Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, et al. Effects of PCSK9 inhibition with Alirocumab on lipoprotein metabolism in healthy humans. Circulation [internet]. 2017;135:352–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27986651, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5262523. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5262523 ID - ref8 ER - TY - STD TI - Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, et al. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. European heart journal [internet]. 2018;39:2577–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29566128. UR - http://www.ncbi.nlm.nih.gov/pubmed/29566128 ID - ref9 ER - TY - STD TI - Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nature reviews endocrinology [internet]. Springer US; 2018;15:52–62. Available from: https://doi.org/10.1038/s41574-018-0110-5,http://www.ncbi.nlm.nih.gov/pubmed/30367179. ID - ref10 ER - TY - STD TI - Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. The journal of biological chemistry [internet]. 2008;283:2363–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18039658. UR - http://www.ncbi.nlm.nih.gov/pubmed/18039658 ID - ref11 ER - TY - STD TI - Demers A, Samami S, Lauzier B, Des Rosiers C, Ngo Sock ET, Ong H, et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arteriosclerosis, thrombosis, and vascular biology [internet]. 2015;35:2517–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26494228. UR - http://www.ncbi.nlm.nih.gov/pubmed/26494228 ID - ref12 ER - TY - STD TI - Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. The journal of clinical investigation [internet]. 1997;100:2170–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9410893, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC508411. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC508411 ID - ref13 ER - TY - STD TI - Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell metabolism [internet]. Elsevier Inc 2010;12:467–82. Available from: https://doi.org/10.1016/j.cmet.2010.09.010, http://www.ncbi.nlm.nih.gov/pubmed/21035758, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2991104. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2991104 ID - ref14 ER - TY - STD TI - Dijk W, Le May C, Cariou B. Beyond LDL: What role for PCSK9 in triglyceride-rich lipoprotein metabolism? Trends in endocrinology and metabolism: TEM [internet]. Elsevier Ltd; 2018;29:420–34. Available from: https://doi.org/10.1016/j.tem.2018.03.013, http://www.ncbi.nlm.nih.gov/pubmed/29665987. UR - http://www.ncbi.nlm.nih.gov/pubmed/29665987 ID - ref15 ER - TY - STD TI - Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nature communications [internet]. 2016;7:11122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27005778, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4814583. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4814583 ID - ref16 ER - TY - STD TI - Sliz E, Kettunen J, Holmes M, Williams C, Boachie C, Wang Q, et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation [internet]. 2018;138:2499–512. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30525347, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6254781. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6254781 ID - ref17 ER - TY - STD TI - Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. European heart journal [internet]. 2018;31:1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30561610. UR - http://www.ncbi.nlm.nih.gov/pubmed/30561610 ID - ref18 ER - TY - STD TI - Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. The analyst [internet]. 2009;134:1781–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19684899. UR - http://www.ncbi.nlm.nih.gov/pubmed/19684899 ID - ref19 ER - TY - STD TI - Würtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA Reductase. Journal of the American College of Cardiology [internet]. 2016;67:1200–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26965542, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4783625. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4783625 ID - ref20 ER - TY - STD TI - Toth PP, Sattar N, Blom DJ, Martin SS, Jones SR, Monsalvo ML, et al. Effect of Evolocumab on lipoprotein particles. The American journal of cardiology [internet]. Elsevier Inc. 2018;121:308–14. Available from: https://doi.org/10.1016/j.amjcard.2017.10.028, http://www.ncbi.nlm.nih.gov/pubmed/29221604. UR - http://www.ncbi.nlm.nih.gov/pubmed/29221604 ID - ref21 ER - TY - STD TI - Yang X-P, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). Journal of lipid research [internet]. 2013;54:2450–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23812625, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3735942. UR - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3735942 ID - ref22 ER - TY - STD TI - Sharma M, Redpath GM, Williams MJA, McCormick SPA. Recycling of Apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circulation research [internet]. 2017;120:1091–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28003220. UR - http://www.ncbi.nlm.nih.gov/pubmed/28003220 ID - ref23 ER - TY - STD TI - McConathy WJ, Trieu VN, Koren E, Wang CS, Corder CC. Triglyceride-rich lipoprotein interactions with Lp(a). Chemistry and physics of lipids [internet]. 1994;67-68:105–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8187204. UR - http://www.ncbi.nlm.nih.gov/pubmed/8187204 ID - ref24 ER - TY - STD TI - Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J, et al. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. Journal of lipid research [internet]. 2001;42:2058–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11734579. UR - http://www.ncbi.nlm.nih.gov/pubmed/11734579 ID - ref25 ER -